New peptide drugs could take aim at a broader range of proteins that cause certain cancers, viral infections, and brain ...

Advances in neovascular macular degeneration, presented at ASRS 2025, include efficacy of aflibercept 8 mg as well as ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

The brain’s map of the body remains largely unaffected by amputation, potentially informing phantom limb pain management and ...

A phase 3 trial suggests reducing the use of cisplatin when treating nasopharyngeal carcinoma with toripalimab-based ...

In nine studies (76 patients), the anti-IgE monoclonal antibody omalizumab (Xolair), given every 2-4 weeks at doses ranging ...

The American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines on deferred umbilical cord clamping ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

Many doctors adopt damaging lifestyle ‘survival skills’ during residency and keep them for years. Here’s how to spot — and ...

An extensive analysis shows scant evidence that ketamine or other NMDA receptor agonists reduce chronic noncancer pain but ...

A UK study shows that ADHD in young women increased during the COVID-19 pandemic, peaking in the age group 20-24 years; ...

In phase 3 APOLLO trial, ATRA-ATO combination therapy showed superior outcomes for high-risk acute promyelocytic leukemia.